CHITA – a registry of in vitro NAMs
If we want to replace animal testing in biomedical research, how do we find human-relevant alternatives? It’s not that simple. There are 1000s of human cell-based assays and systems that…
Researchers are using phenotypic assays at earlier and earlier stages of drug discovery. Assays for use in hit triage must be exceptional. In a previous post we’ve described the impact…
Drug discovery practitioners are painfully familiar with “nuisance” compounds. These compounds may be screening hits that start out as promising actives but then are later discovered to be artifacts or…
Quietly happening beneath the radar, phenotypic platforms are becoming integrated into drug discovery processes. Why this is happening and how are phenotypic assays transforming the stages of drug discovery? Multiple…
It takes courage to address common pitfalls in drug discovery and perseverance to traverse the route. In my work and as an advisor I’ve seen 100s of early-stage drug discovery…
Is coronavirus morbidity exacerbated by environmental pollution? A potential mechanism underlying thrombosis-related side effects connects multiple known risk factors. In the early days of the COVID-19 pandemic, signs that infected…
How can we incorporate human-based animal alternatives into drug discovery? Can we reduce animal testing and still improve program success? Making good decisions requires integrating information from many assays and…
A strong chain of translatability is crucial for successful drug discovery programs. The chain of translatability is a molecular-level association between the mechanisms that drive the assay phenotype, the preclinical disease…
The recent failure of the IDO inhibitor epacadostat in combination with Merck’s pembrolizumab for immuno-oncology (IO) has been the subject of numerous reports and commentary (see here, here, here and Vinay Prasad’s epic twitter rant here). And now today…
This new article in DDW adds to some very good recent perspectives on phenotypic drug discovery (PDD) from the pharma industry in NRDD and ADDT (see additional articles and further…
If phenotypic screening is driving innovation in drug discovery, network biology is the fuel. In phenotypic screening, compounds are tested for their functional effects on cellular responses in a target agnostic…
